Home › Trials › NCT06582342

Comparing 3D imaging to CT for assessing pancreatic cancer treatment response

Is 3-D Imaging Technology Superior to Computed Tomography in Assessing Response to Neoadjuvant Treatment in Patients With Borderline or Locally Advanced Pancreatic Adenocarcinoma?

Observational Fundación para la Investigación del Hospital Clínico de Valencia · NCT06582342

This study is testing if a new 3D imaging method is better than regular CT scans at showing how well chemotherapy is working for patients with certain types of pancreatic cancer before surgery.

Quick facts

Study typeObservational
Enrollment70 (estimated)
Ages18 Years and up
SexAll
SponsorFundación para la Investigación del Hospital Clínico de Valencia Academic / other
Drugs / interventionschemotherapy
Locations17 sites (Alicante and 16 other locations)
Trial IDNCT06582342 on ClinicalTrials.gov

What this trial studies

This prospective multicenter study aims to evaluate the effectiveness of 3D-MSP imaging technology compared to traditional CT scans in assessing the response of patients with borderline or locally advanced pancreatic adenocarcinoma to neoadjuvant chemotherapy. Patients will undergo both imaging techniques prior to surgical exploration, allowing for a direct comparison of their accuracy in predicting surgical outcomes. The study will analyze various accuracy metrics, including sensitivity and specificity, against the gold standard of surgical and histopathological results. By utilizing a within-patient control design, each participant serves as their own control, enhancing the reliability of the findings.

Who should consider this trial

Good fit: Ideal candidates are adults diagnosed with borderline or locally advanced pancreatic adenocarcinoma who have received neoadjuvant chemotherapy and are scheduled for surgical exploration.

Not a fit: Patients who are younger than 18 years, have experienced disease progression during treatment, or have not undergone a preoperative CT scan will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve the accuracy of preoperative assessments, potentially leading to better surgical outcomes for patients with pancreatic cancer.

How similar studies have performed: While the use of advanced imaging technologies is gaining traction, this study represents a novel approach as there are currently no prospective validation studies specifically comparing 3D-MSP technology to CT in this patient population.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

\- Patients with a diagnosis of borderline or locally advanced PAC of the head of the pancreas, as defined by the National Comprehensive Cancer Network (NCCN), who have received neoadjuvant treatment and who undergo surgical exploration with resective intent.

Exclusion Criteria:

* Patients younger than 18 years of age.
* Patients under 18 years of age.
* Disease progression during neoadjuvant treatment.
* No preoperative CT scan.
* Refusal to participate in the study.

Where this trial is running

Alicante and 16 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Adenocarcinoma of the Pancreas
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.